Emily Menendez

GU Oncology Now

The efficacy of first-line (1L) immune checkpoint inhibitor (ICI) combination therapies among different subgroups of patients with metastatic renal cell carcinoma (mRCC) remains unclear. Using data from up-to-date clinical trials, researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy <a href="https://kcrs.kidneycan.org/wp-content/uploads/2023/07/KCRS23-Abstract-Book-v3.pdf" target="_blank" rel="noopener">as a 1L treatment for mRCC.</a>Researchers used the MEDLINE and Embase databases to search for relevant phase 2 and 3 randomized, controlled trials that assessed ICI combination therapies in 1L mRCC. Efficacy was reported by age (&lt;65 years; &gt;65 years), gender, programmed cell death 1 ligand 1 (PD-L1) receptor status, and International mRCC Database Consortium risk category (favorable; intermediate/poor [IP]).Efficacy outcomes included overall survival (OS), progression-free survival, and objective response rate. A random-effects meta-analysis was conducted, and a P-value of interaction &lt;0.1 indicated statistical significance.In 6 trials that included a total of 5121 patients, ICI combinations improved OS in the overall and IP-risk (hazard ratio, 0.67; 95% CI, 0.60-0.75) populations compared with sunitinib, but not in the favorable-risk population (0.98; 0.76-1.27).Female patients achieved a greater benefit with ICI combinations over male patients (females, 0.64; 0.53-0.77; males, 0.77; 0.69-0.86; P=.09), and younger patients had a significant OS benefit compared with older patients (&lt;65 years, 0.64; 0.57-0.73; &gt;65 years, 0.84; 0.69-1.01; P=.02).Patients with mRCC and factors including female gender, younger age (&lt;65 years), and IP disease risk may benefit more from ICI combination therapies.

ICI Combinations Provide More Benefit for Female Patients With mRCC

Advanced Renal Cell Carcinoma

Using data from up-to-date clinical trials, researchers from the Mayo Clinic assessed the efficacy of ICI combination therapy as a first-line mRCC treatment.

ICI Combinations Benefit Female Patients With mRCC

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe